In the past few years pharmaceutical companies have developed a string of new Alzheimer’s drugs called anti-amyloids, which target amyloid plaques in patients’ brains. These plaques are one of the key biomarkers of the disease.
The first of these drugs, Aduhelm, was approved by the FDA in 2021 amid enormous controversy. The FDA approved the drug despite little evidence that it actually slowed cognitive decline in patients. Biogen, the maker of Aduhelm, pulled the plug on further research or sales of the drug last month.
In January 2023 The FDA approved another anti-amyloid medication from Biogen, lecanemab, sold under the brand name Leqembi. This time, there was much stronger evidence. Clinical trial results showed that the drug showed a modest improvement in cognitive decline in the early phases of the disease. But the drug comes with risks, including brain swelling and bleeding.
Most recently, at the beginning of March, the FDA delayed approval of another anti-amyloid drug, donanemab, created by Eli Lilly. The FDA said it will be conducting an additional review to further scrutinize the study design and efficacy data.
From the outside looking in, these Alzheimer’s drugs appear to be mired in controversy. How well do they actually work? And why has there been so much back and forth with the FDA?
To answer those questions and more, guest host Arielle Duhaime-Ross talks with Dr. Jason Karlawish, professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine, and co-director of the Penn Memory Center.
Transcripts for each segment will be available after the show airs on sciencefriday.com.
Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.
Introducing Our New Podcast: Universe Of Art
Anesthesia 101, Carbon-Sequestering Poplars, Period Book. April 21, 2023, Part 1
The Myth of the Alpha Wolf, Cherokee Nation Seed Banks, History of Gender Affirming Care. April 21, 2023, Part 2
‘Possibility Of Life’ Book, PFAS Sewage, ‘Smart’ Play. April 14, 2023, Part 2
EV Proposal, Lactose Intolerance. April 14, 2023, Part 1
Artemis II Astronauts, AI Research Pause, Terra Nil Video Game. April 7, 2023, Part 2
Plants Make Sounds, Frog Science, COVID Vaccine Update. April 7, 2023, Part 1
Mapping An Insect Brain, Climate Education, Audubon Name, Wastewater Methane. March 31, 2023, Part 2
Early Spring, Mumps On The Rise, Gulf Of Maine, Supermassive Black Hole. March 31, 2023, Part 1
New NASA Science Head, Climate and Fungus, Whiskey Fungus, Animal Testing Alternatives. March 24, 2023, Part 2
March Mammal Madness, Underwater Volcano, Listening to Space. March 24th, 2023, Part 1
Smart Toilet, Soft Robotics, Naked Mole Rats. March 17, 2023, Part 2
Drugs Designed By AI, The Phosphorus Paradox, Regulating PFAS Chemicals. March 17, 2023, Part 1
Tips And Tricks To Grow Your Garden In A Changing Climate. March 10, 2023, Part 2
A New Controversial Black Hole Theory, Saving The Great Salt Lake. March 10, 2023, Part 1
Science At The Oscars, Finding Shackleton’s “Endurance” Ship. March 3, 2023, Part 1
Social Media’s ‘Chaos Machine,’ Whale Vocal Fry, Distant Galaxies. March 3, 2023, Part 2
AI And Hip Hop, Self-Planting Seeds, Abortion Pill Facing Restrictions. Feb 24, 2023, Part 1
“All That Breathes’ Film, Repatriating Native American Remains, Benjamin Banneker. Feb 24, 2023, Part 2
Spy Balloons, Cost of Cancer Care, Seaweed, Chocolate Mouthfeel. Feb 17, 2023, Part 2
Create your
podcast in
minutes
It is Free
The Modern West
Just Dumb Enough Podcast
Voices of Misery Podcast
House of Whimsical Terror
Stuff You Should Know
Timcast IRL